Pascal Soriot (Sipa via AP Images)
July 29, 2021 10:17 AM EDT
Pharma
Coronavirus

A tale of two vac­cines: As­traZeneca's shot still a block­buster, but Pfiz­er sales are on an­oth­er lev­el

Max Gelman

Senior Editor

With As­traZeneca’s sec­ond quar­ter earn­ings call Thurs­day morn­ing came up­dat­ed sales num­bers for its Covid-19 vac­cine — and com­pared to the big mR­NA play­ers, the num­bers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

US with­draw­al from WHO could jeop­ar­dize in­for­ma­tion shar­ing

Sanofi says no sup­ply in­ter­rup­tions af­ter land­ing FDA warn­ing let­ter for US site

Re­newed mifepri­s­tone fight will be ear­ly test of Trump’s abor­tion stance in his sec­ond term

J&J's Spra­va­to wins ex­pand­ed la­bel for de­pres­sion as sin­gu­lar treat­ment

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times